Skip to content
Review Open access

Advances in improving cancer immunotherapy with nanotechnology: from smart nanoparticles to synergistic combination strategies

Jul 2026 · Molecular Cancer · Vol 25 · 0 citations · 413 references
Medicine

TL;DR

This review comprehensively highlights the latest advancements in using nanotechnology to enhance cancer immunotherapy and highlights synergistic effects achieved by combining nanoparticles with other treatments like chemotherapy, radiation, photothermal/photodynamic therapy, and more, which can turn hard-to-treat tumors into susceptible targets.

Abstract

Cancer immunotherapy has substantially advanced cancer treatment, achieving durable responses in select malignancies. However, its widespread application is limited by significant challenges: low efficacy in many solid tumors, severe side effects, and immune evasion facilitated by the tumor microenvironment (TME). Nanotechnology offers a promising approach to address these obstacles. By employing nanoparticles (NPs), we can precisely deliver therapeutics to tumor sites, ensure controlled release to minimize side effects, and amplify the immune response, thereby substantially boosting the effectiveness of immunotherapy. This review comprehensively highlights the latest advancements in using nanotechnology to enhance cancer immunotherapy. This paper details various applications of nanotech in this field. It discusses smart nanoparticles that respond to TME signals to release drugs (e.g., checkpoint inhibitors) directly at the tumor, reducing systemic side effects and activating T-cells. We also explore how nanovaccines, which co-deliver tumor markers and immune boosters, can induce antigen-specific immune responses. Furthermore, mRNA-loaded nanoparticles can directly modify CAR T-cells inside the body, simplifying treatment and increasing efficacy. Strategies like using PLGA NPs to deliver immune enhancers such as IL-2 are also presented, which activate immune cells while minimizing systemic issues. The review also explains how nanoparticles can re-engineer the immunosuppressive TME to create an environment more conducive to immune action. We also emphasize that nanotechnology-enhanced adoptive therapies, particularly cytokine-induced killer (CIK) cell immunotherapy, hold great potential to improve tumor targeting, treatment persistence durability, and overall anticancer efficacy. Collectively, we highlight synergistic effects achieved by combining nanoparticles with other treatments like chemotherapy, radiation, photothermal/photodynamic therapy, and more, which can turn hard-to-treat tumors into susceptible targets. The integration of nanotechnology and immunotherapy holds the potential to meaningfully advance future cancer therapy.

Read PDF

Similar papers

Review Open access Aug 2026

Polymeric Nanoparticles for Precision Tumor Immunotherapy: Rational Design Strategies and Spatiotemporal Immune Activation

This review critically evaluate PNP design strategies, emphasizing stimuli-responsive release mechanisms that enable spatiotemporally controlled drug delivery within the TME, thereby enhancing efficacy and minimizing systemic toxicity.

Dong-Qi Li, Jia Hu, Ying-Shu Cui et al. · 1 citation
Review Aug 2026

Nano meets CAR-T: A new era in cancer immunotherapy.

This review article focuses on CAR-T cell bioengineering, antitumor mechanism of action, challenges and limitations, as well as the latest innovative nanotechnological solutions for complementing CAR-T cell immunotherapy.

Alaa Ibrahim, Maha Nasr · 1 citation
Review Jul 2026

Nanomedicine-Based Therapeutic Strategies for Next-Generation Cancer Immunotherapy.

Cancer immunotherapy has reshaped cancer treatment by enabling the immune system to recognize and eliminate tumor cells. Nevertheless, its clinical translation remains limited by suboptimal response rates, poor penetration into deep tumor tissues, and insufficient therapeutic efficacy. Cancer immunotherapy alone is oft...

Brynne Shu Ni Tan, Yanli Zhao · 0 citations
Review Open access Jul 2026

Personalized cancer vaccines: bridging immune-oncology and precision medicine for advanced therapeutics

Next-generation personalized cancer vaccines are advancing the transition from reactive treatment to proactive, precision-controlled cancer immunotherapy, and when integrated with artificial intelligence for antigen selection and multiomics for patient stratification, these platforms accelerate vaccine design and impro...

L. Ye, GuoWei Zhao, Jiaxiu Ma et al. · 1 citation
Review Open access Aug 2026

RNA Nanotechnology for Reversal of Melanoma Immunotherapy Resistance

Purpose: Cancer immunotherapy works by targeting immune and cancer cell checkpoints to induce long-term anti-tumor responses, showing effectiveness in inhibiting tumor growth and preventing recurrence. However, clinical trials have also reported side effects, as well as resistance in some patients with melanoma, prompt...

Mojtaba Tarin, Mahsa Akbari Oryani, Sareh Etemad et al. · 0 citations
Review Sep 2026

Emerging biodegradable nanomaterials for innovative tumor immunotherapy.

The biodegradable nanomaterials exhibit promising potential for tumor immunotherapy due to their unique advantages including biodegradability, simple and cost-effective synthesis, and use of renewable resources, aligning with environmental and sustainable development goals.

Ru-Tuan Dong, Shuai-Shuai Ding, Bo-Kai Song et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.